메뉴 건너뛰기




Volumn 44, Issue 2, 2005, Pages 147-173

Individualised cancer chemotherapy: Strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: A review

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CARBOPLATIN; CISPLATIN; CYTARABINE; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; HEXAMETHYLENEBISACETAMIDE; MELPHALAN; METHOTREXATE; PACLITAXEL; SURAMIN; TENIPOSIDE; TOPOTECAN;

EID: 13244298666     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200544020-00002     Document Type: Review
Times cited : (102)

References (104)
  • 1
  • 2
    • 0026716425 scopus 로고
    • Revisiting some factors contributing to variability
    • Gibaldi M. Revisiting some factors contributing to variability. Ann Pharmacother 1992; 26 (7/8): 1002-7
    • (1992) Ann Pharmacother , vol.26 , Issue.7-8 , pp. 1002-1007
    • Gibaldi, M.1
  • 3
    • 0029743058 scopus 로고    scopus 로고
    • Dose calculation of anticancer drugs: A review of the current practice and introduction of an alternative
    • Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996; 14 (9): 2590-611
    • (1996) J Clin Oncol , vol.14 , Issue.9 , pp. 2590-2611
    • Gurney, H.1
  • 4
    • 0023618618 scopus 로고
    • Therapeutic drug monitoring in oncology: Problems and potential in antineoplastic therapy
    • Moore MJ, Erlichman C. Therapeutic drug monitoring in oncology: problems and potential in antineoplastic therapy. Clin Pharmacokinet 1987; 13: 205-27
    • (1987) Clin Pharmacokinet , vol.13 , pp. 205-227
    • Moore, M.J.1    Erlichman, C.2
  • 6
  • 7
    • 0034056182 scopus 로고    scopus 로고
    • Adaptive control methods for the dose individualisation of anticancer agents
    • Rousseau A, Marquet P, Debord J, et al. Adaptive control methods for the dose individualisation of anticancer agents. Clin Pharmacokinet 2000; 38 (4): 315-53
    • (2000) Clin Pharmacokinet , vol.38 , Issue.4 , pp. 315-353
    • Rousseau, A.1    Marquet, P.2    Debord, J.3
  • 8
    • 0024360395 scopus 로고
    • Clinical pharmacokinetics-pharmacodynamics of anticancer drugs
    • Evans W, Relling M. Clinical pharmacokinetics-pharmacodynamics of anticancer drugs. Clin Pharmacokinet 1989; 16: 327-36
    • (1989) Clin Pharmacokinet , vol.16 , pp. 327-336
    • Evans, W.1    Relling, M.2
  • 9
    • 0025873389 scopus 로고
    • Pharmacokinetic optimisation of anti-cancer therapy
    • Liliemark J, Peterson C. Pharmacokinetic optimisation of anti-cancer therapy. Clin Pharmacokinet 1991; 21 (3): 213-31
    • (1991) Clin Pharmacokinet , vol.21 , Issue.3 , pp. 213-231
    • Liliemark, J.1    Peterson, C.2
  • 11
    • 0030749434 scopus 로고    scopus 로고
    • Therapeutic drug monitoring opportunities in cancer therapy
    • McLeod HL. Therapeutic drug monitoring opportunities in cancer therapy. Pharmacol Ther 1997; 74 (1): 39-54
    • (1997) Pharmacol Ther , vol.74 , Issue.1 , pp. 39-54
    • McLeod, H.L.1
  • 12
    • 0027429687 scopus 로고
    • Therapeutic drug monitoring in cancer management
    • Galpin AJ, Evans WE. Therapeutic drug monitoring in cancer management. Clin Chem 1993; 39 (11B): 2419-30
    • (1993) Clin Chem , vol.39 , Issue.11 B , pp. 2419-2430
    • Galpin, A.J.1    Evans, W.E.2
  • 13
    • 0030892991 scopus 로고    scopus 로고
    • Pharmacokinetic optimization of cancer chemotherapy: Effect on outcomes
    • Masson E, Zamboni WC. Pharmacokinetic optimization of cancer chemotherapy: effect on outcomes. Clin Pharmacokinet 1997; 32 (4): 324-43
    • (1997) Clin Pharmacokinet , vol.32 , Issue.4 , pp. 324-343
    • Masson, E.1    Zamboni, W.C.2
  • 14
    • 0003136034 scopus 로고    scopus 로고
    • Individualized dosing of anti-cancer drugs and the role of therapeutic monitoring
    • Grochow LB, Ames MM, editors. Baltimore (MD): Williams & Wilkins
    • Grochow LB. Individualized dosing of anti-cancer drugs and the role of therapeutic monitoring. In: Grochow LB, Ames MM, editors. A clinician's guide to chemotherapy pharmacokinetics and pharmacodynamics. Baltimore (MD): Williams & Wilkins, 1998: 3-16
    • (1998) A Clinician's Guide to Chemotherapy Pharmacokinetics and Pharmacodynamics , pp. 3-16
    • Grochow, L.B.1
  • 15
    • 0343090967 scopus 로고    scopus 로고
    • Making TDM work to optimize cancer chemotherapy: A multidisciplinary team approach
    • Hon YY, Evans WE. Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach. Clin Chem 1998; 44 (2): 388-400
    • (1998) Clin Chem , vol.44 , Issue.2 , pp. 388-400
    • Hon, Y.Y.1    Evans, W.E.2
  • 16
    • 0027787737 scopus 로고
    • Pharmacodynamic-pharmacokinetic relationships and therapeutic drug monitoring
    • Workman P, Graham MA, editors. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press
    • Kobayashi K, Jodrell DI, Ratain MJ. Pharmacodynamic-pharmacokinetic relationships and therapeutic drug monitoring. In: Workman P, Graham MA, editors. Pharmacokinetics and cancer chemotherapy. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press, 1993: 51-78
    • (1993) Pharmacokinetics and Cancer Chemotherapy , pp. 51-78
    • Kobayashi, K.1    Jodrell, D.I.2    Ratain, M.J.3
  • 17
    • 0036399707 scopus 로고    scopus 로고
    • Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs
    • Rousseau A, Marquet P. Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. Fundam Clin Pharmacol 2002; 16: 253-62
    • (2002) Fundam Clin Pharmacol , vol.16 , pp. 253-262
    • Rousseau, A.1    Marquet, P.2
  • 18
    • 0027418925 scopus 로고
    • Individualizing dosing of cancer chemotherapy
    • Kobayashi K, Ratain MJ. Individualizing dosing of cancer chemotherapy. Semin Oncol 1993; 20 (1): 30-42
    • (1993) Semin Oncol , vol.20 , Issue.1 , pp. 30-42
    • Kobayashi, K.1    Ratain, M.J.2
  • 19
    • 0032422726 scopus 로고    scopus 로고
    • Practical treatment guide for dose individualisation in cancer chemotherapy
    • Canal P, Chatelut E, Guichard S. Practical treatment guide for dose individualisation in cancer chemotherapy. Drugs 1998; 56 (6): 1019-38
    • (1998) Drugs , vol.56 , Issue.6 , pp. 1019-1038
    • Canal, P.1    Chatelut, E.2    Guichard, S.3
  • 20
    • 0034851530 scopus 로고    scopus 로고
    • Therapeutic drug monitoring for cytotoxic drugs
    • Lennard L. Therapeutic drug monitoring for cytotoxic drugs. Br J Clin Pharmacol 2001; 52: 75-87S
    • (2001) Br J Clin Pharmacol , vol.52
    • Lennard, L.1
  • 21
    • 0028342646 scopus 로고
    • Individual dose adaptation of anticancer drugs
    • Desoize B, Robert J. Individual dose adaptation of anticancer drugs. Eur J Cancer 1994; 30A (6): 844-51
    • (1994) Eur J Cancer , vol.30 A , Issue.6 , pp. 844-851
    • Desoize, B.1    Robert, J.2
  • 22
    • 0034971415 scopus 로고    scopus 로고
    • Concentration-controlled or effect-controlled trials: Useful alternatives to conventional dose-controlled trials?
    • Grahnen A, Karlsson MO. Concentration-controlled or effect-controlled trials: useful alternatives to conventional dose-controlled trials? Clin Pharmacokinet 2001; 40 (5): 317-25
    • (2001) Clin Pharmacokinet , vol.40 , Issue.5 , pp. 317-325
    • Grahnen, A.1    Karlsson, M.O.2
  • 23
    • 0027323727 scopus 로고
    • Busulphan disposition: The role of therapeutic monitoring in bone marrow transplantation induction regimens
    • Grochow LB. Busulphan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 1993; 20 (4) Suppl. 4: 18-25
    • (1993) Semin Oncol , vol.20 , Issue.4 SUPPL. 4 , pp. 18-25
    • Grochow, L.B.1
  • 24
    • 13344259305 scopus 로고    scopus 로고
    • Association of busulphan area under the curve with veno-occlusive disease following BMT
    • Dix SP, Wingard JR, Mullins RE, et al. Association of busulphan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996; 17 (2): 225-30
    • (1996) Bone Marrow Transplant , vol.17 , Issue.2 , pp. 225-230
    • Dix, S.P.1    Wingard, J.R.2    Mullins, R.E.3
  • 25
    • 0029866142 scopus 로고    scopus 로고
    • Busulphan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: Phase I dose escalation of busulphan based on targeted plasma levels
    • Demirer T, Buckner CD, Appelbaum FR, et al. Busulphan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: phase I dose escalation of busulphan based on targeted plasma levels. Bone Marrow Transplant 1996; 17 (4): 491-5
    • (1996) Bone Marrow Transplant , vol.17 , Issue.4 , pp. 491-495
    • Demirer, T.1    Buckner, C.D.2    Appelbaum, F.R.3
  • 26
    • 0029927901 scopus 로고    scopus 로고
    • Busulphan, cyclophosphamide and fractionated total body irradiation for allogenic marrow transplantation for advanced acute and chronic myelogenous leukemia: Phase I dose escalation of busulphan based on targeted plasma levels
    • Demirer T, Buckner CD, Appelbaum FR, et al. Busulphan, cyclophosphamide and fractionated total body irradiation for allogenic marrow transplantation for advanced acute and chronic myelogenous leukemia: phase I dose escalation of busulphan based on targeted plasma levels. Bone Marrow Transplant 1996; 17 (3): 341-6
    • (1996) Bone Marrow Transplant , vol.17 , Issue.3 , pp. 341-346
    • Demirer, T.1    Buckner, C.D.2    Appelbaum, F.R.3
  • 27
    • 0030818478 scopus 로고    scopus 로고
    • An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children
    • Chattergoon DS, Saunders EF, Klein J, et al. An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children. Bone Marrow Transplant 1997; 20 (5): 347-54
    • (1997) Bone Marrow Transplant , vol.20 , Issue.5 , pp. 347-354
    • Chattergoon, D.S.1    Saunders, E.F.2    Klein, J.3
  • 28
    • 0008014475 scopus 로고    scopus 로고
    • Pharmacodynamic, pharmacokinetic and plasma monitoring of busulphan in pediatric patients undergoing bone marrow transplantation
    • Regazzi MB, Locatelli F, Buggia I, et al. Pharmacodynamic, pharmacokinetic and plasma monitoring of busulphan in pediatric patients undergoing bone marrow transplantation [abstract]. Ther Drug Monit 1997; 19: 597
    • (1997) Ther Drug Monit , vol.19 , pp. 597
    • Regazzi, M.B.1    Locatelli, F.2    Buggia, I.3
  • 29
    • 4243881136 scopus 로고    scopus 로고
    • Target dose adjustment of busulphan using pharmacokinetic parameters in pediatric patients undergoing bone marrow transplantation for malignancy or genetic disease
    • Bolinger AM, Zangwill AB, Slattery JT, et al. Target dose adjustment of busulphan using pharmacokinetic parameters in pediatric patients undergoing bone marrow transplantation for malignancy or genetic disease [abstract]. Blood 1999; 94: 145a
    • (1999) Blood , vol.94
    • Bolinger, A.M.1    Zangwill, A.B.2    Slattery, J.T.3
  • 30
    • 0033832458 scopus 로고    scopus 로고
    • Individualising high-dose oral busulfan: Prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies
    • Tran HT, Madden T, Petropoulos D, et al. Individualising high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies. Bone Marrow Transplant 2000; 26 (5): 463-70
    • (2000) Bone Marrow Transplant , vol.26 , Issue.5 , pp. 463-470
    • Tran, H.T.1    Madden, T.2    Petropoulos, D.3
  • 31
    • 0030998359 scopus 로고    scopus 로고
    • A Bayesian dosing method for carboplatin given by continuous infusion for 120h
    • Guillet P, Monjanel S, Nicoara A, et al. A Bayesian dosing method for carboplatin given by continuous infusion for 120h. Cancer Chemother Pharmacol 1997; 40 (2): 143-9
    • (1997) Cancer Chemother Pharmacol , vol.40 , Issue.2 , pp. 143-149
    • Guillet, P.1    Monjanel, S.2    Nicoara, A.3
  • 32
    • 0030985776 scopus 로고    scopus 로고
    • Phase I pharmacokinetic study of multicycle high-dose carboplatin followed by peripheral-blood stem-cell infusion in patients with cancer
    • Johansen MJ, Madden T, Mehra RC, et al. Phase I pharmacokinetic study of multicycle high-dose carboplatin followed by peripheral-blood stem-cell infusion in patients with cancer. J Clin Oncol 1997; 15 (4): 1481-91
    • (1997) J Clin Oncol , vol.15 , Issue.4 , pp. 1481-1491
    • Johansen, M.J.1    Madden, T.2    Mehra, R.C.3
  • 33
    • 0033975709 scopus 로고    scopus 로고
    • A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage
    • Chatelut E, Pivot X, Otto J, et al. A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage. Eur J Cancer 2000; 36 (2): 264-9
    • (2000) Eur J Cancer , vol.36 , Issue.2 , pp. 264-269
    • Chatelut, E.1    Pivot, X.2    Otto, J.3
  • 34
    • 13244286080 scopus 로고    scopus 로고
    • Optimization of high dose carboplatin treatment in children with stage IV soft tissue sarcoma (SIOP/UKCCSG MMT 98 study) by real-time pharmacokinetic monitoring
    • Veal GJ, Foot A, McDowell H, et al. Optimization of high dose carboplatin treatment in children with stage IV soft tissue sarcoma (SIOP/UKCCSG MMT 98 study) by real-time pharmacokinetic monitoring [abstract]. Proc Am Assoc Cancer Res 2002; 43: 275
    • (2002) Proc Am Assoc Cancer Res , vol.43 , pp. 275
    • Veal, G.J.1    Foot, A.2    McDowell, H.3
  • 35
    • 0013637687 scopus 로고
    • Evaluation prospective d'une méthode d'adaptation de posologie du cisplatine
    • Desoize B, Dumont P, Manot L, et al. Evaluation prospective d'une méthode d'adaptation de posologie du cisplatine [abstract]. Bull Cancer 1995; 82: 411
    • (1995) Bull Cancer , vol.82 , pp. 411
    • Desoize, B.1    Dumont, P.2    Manot, L.3
  • 36
    • 0034843961 scopus 로고    scopus 로고
    • Adaptive intrapatient dose escalation of cisplatin in patients with advanced head and neck cancer
    • Schellens JHM, Planting AS, Ma J, et al. Adaptive intrapatient dose escalation of cisplatin in patients with advanced head and neck cancer. Anticancer Drugs 2001; 12 (8): 667-75
    • (2001) Anticancer Drugs , vol.12 , Issue.8 , pp. 667-675
    • Schellens, J.H.M.1    Planting, A.S.2    Ma, J.3
  • 37
    • 0021847172 scopus 로고
    • Pharmacologically directed Ara-C therapy for refractory leukemia
    • Plunkett W, Iacoboni S, Estey E, et al. Pharmacologically directed Ara-C therapy for refractory leukemia. Semin Oncol 1985; 12 (2) Suppl. 3: 20-30
    • (1985) Semin Oncol , vol.12 , Issue.2 SUPPL. 3 , pp. 20-30
    • Plunkett, W.1    Iacoboni, S.2    Estey, E.3
  • 38
    • 0024589605 scopus 로고
    • Adaptive control of etoposide administration: Impact of interpatient pharmacodynamic variability
    • Ratain MJ, Schilski RL, Choi KE, et al. Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability. Clin Pharm Ther 1989; 45 (3): 226-33
    • (1989) Clin Pharm Ther , vol.45 , Issue.3 , pp. 226-233
    • Ratain, M.J.1    Schilski, R.L.2    Choi, K.E.3
  • 39
    • 0025744506 scopus 로고
    • Pharmacologically based dosing of etoposide: A means of safely increasing dose intensity
    • Ratain MJ, Mick R, Schilsky RL, et al. Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity. J Clin Oncol 1991; 9 (8): 1480-6
    • (1991) J Clin Oncol , vol.9 , Issue.8 , pp. 1480-1486
    • Ratain, M.J.1    Mick, R.2    Schilsky, R.L.3
  • 40
    • 2642572069 scopus 로고
    • Disposition of etoposide (VP-16) in children with acute nonlymphocytic leukemia (ANLL)
    • Madden T, Crom WR, Mirro J. Disposition of etoposide (VP-16) in children with acute nonlymphocytic leukemia (ANLL) [abstract]. Clin Pharmacol Ther 1990; 47: 206
    • (1990) Clin Pharmacol Ther , vol.47 , pp. 206
    • Madden, T.1    Crom, W.R.2    Mirro, J.3
  • 41
    • 0029935554 scopus 로고    scopus 로고
    • Therapeutic drug monitoring of etoposide in a 14-day infusion for non-small-cell lung cancer
    • Ando Y, Minami H, Saka H, et al. Therapeutic drug monitoring of etoposide in a 14-day infusion for non-small-cell lung cancer. Jpn J Cancer Res 1996; 87 (2): 200-5
    • (1996) Jpn J Cancer Res , vol.87 , Issue.2 , pp. 200-205
    • Ando, Y.1    Minami, H.2    Saka, H.3
  • 42
    • 0029789372 scopus 로고    scopus 로고
    • Therapeutic drug monitoring in 21-day oral etoposide treatment for lung cancer
    • Ando Y, Minami H, Saka H, et al. Therapeutic drug monitoring in 21-day oral etoposide treatment for lung cancer. Jpn J Cancer Res 1996; 87 (8): 856-61
    • (1996) Jpn J Cancer Res , vol.87 , Issue.8 , pp. 856-861
    • Ando, Y.1    Minami, H.2    Saka, H.3
  • 43
    • 8944246796 scopus 로고    scopus 로고
    • Therapeutic drug monitoring of continuous infusion etoposide in small-cell lung cancer
    • Joel SP, Ellis P, O'Byrne K, et al. Therapeutic drug monitoring of continuous infusion etoposide in small-cell lung cancer. J Clin Oncol 1996; 14 (6): 1903-12
    • (1996) J Clin Oncol , vol.14 , Issue.6 , pp. 1903-1912
    • Joel, S.P.1    Ellis, P.2    O'Byrne, K.3
  • 44
    • 0030480554 scopus 로고    scopus 로고
    • Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: A cancer research campaign phase I/II committee study
    • Porter D, Boddy A, Thomas H, et al. Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee study. Semin Oncol 1996; 23 (6) Suppl. 13: 34-44
    • (1996) Semin Oncol , vol.23 , Issue.6 SUPPL. 13 , pp. 34-44
    • Porter, D.1    Boddy, A.2    Thomas, H.3
  • 45
    • 0031743076 scopus 로고    scopus 로고
    • A randomised, concentration-controlled, comparison of standard (5-day) vs prolonged (15-day) infusions of etoposide phosphate in small-cell lung cancer
    • Joel S, O'Byrne K, Penson R, et al. A randomised, concentration- controlled, comparison of standard (5-day) vs prolonged (15-day) infusions of etoposide phosphate in small-cell lung cancer. Ann Oncol 1998; 9: 1205-11
    • (1998) Ann Oncol , vol.9 , pp. 1205-1211
    • Joel, S.1    O'Byrne, K.2    Penson, R.3
  • 46
    • 0031744483 scopus 로고    scopus 로고
    • Therapeutic drug monitoring of 21-day oral etoposide in patients with advanced non-small cell lung cancer
    • Miller AA, Tolley EA, Niell HB. Therapeutic drug monitoring of 21-day oral etoposide in patients with advanced non-small cell lung cancer. Clin Cancer Res 1998; 4 (7): 1705-10
    • (1998) Clin Cancer Res , vol.4 , Issue.7 , pp. 1705-1710
    • Miller, A.A.1    Tolley, E.A.2    Niell, H.B.3
  • 47
    • 0031775809 scopus 로고    scopus 로고
    • A study of the feasibility and accuracy of pharmacokinetically guided etoposide dosing in children
    • Lowis SP, Price L, Pearson ADJ, et al. A study of the feasibility and accuracy of pharmacokinetically guided etoposide dosing in children. Br J Cancer 1998; 77 (12): 2318-23
    • (1998) Br J Cancer , vol.77 , Issue.12 , pp. 2318-2323
    • Lowis, S.P.1    Price, L.2    Pearson, A.D.J.3
  • 48
    • 0036890583 scopus 로고    scopus 로고
    • Population pharmacokinetics of etoposide: Application to therapeutic drug monitoring
    • Ciccolini J, Monjanel-Mouterde S, Bun SS, et al. Population pharmacokinetics of etoposide: application to therapeutic drug monitoring. Ther Drug Monit 2002; 24 (6): 709-14
    • (2002) Ther Drug Monit , vol.24 , Issue.6 , pp. 709-714
    • Ciccolini, J.1    Monjanel-Mouterde, S.2    Bun, S.S.3
  • 49
    • 0024512054 scopus 로고
    • 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer
    • Santini J, Milano G, Thyss A, et al. 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer 1989; 59 (2): 287-90
    • (1989) Br J Cancer , vol.59 , Issue.2 , pp. 287-290
    • Santini, J.1    Milano, G.2    Thyss, A.3
  • 50
    • 0027278648 scopus 로고
    • Surveillance pharmacokinétique avec adaptation de posologie du 5-fluorouracile administré en perfusion continue
    • Wihlm J, Levêque D, Velten M, et al. Surveillance pharmacokinétique avec adaptation de posologie du 5-fluorouracile administré en perfusion continue. Bull Cancer 1993; 80: 439-45
    • (1993) Bull Cancer , vol.80 , pp. 439-445
    • Wihlm, J.1    Levêque, D.2    Velten, M.3
  • 51
    • 0028568929 scopus 로고
    • Clinical randomized study of 5-FU monitoring versus standard dose in patients with head and neck cancer: Preliminary results
    • Fety R, Rolland F, Barberi-Heyob M, et al. Clinical randomized study of 5-FU monitoring versus standard dose in patients with head and neck cancer: preliminary results. Anticancer Res 1994; 14 (6A): 2347-52
    • (1994) Anticancer Res , vol.14 , Issue.6 A , pp. 2347-2352
    • Fety, R.1    Rolland, F.2    Barberi-Heyob, M.3
  • 52
    • 0031696544 scopus 로고    scopus 로고
    • Clinical impact of pharmacokinetically guided adaptation of 5-fluorouracil: Results from a multicentre, randomized trial in patients with locally advanced head and neck carcinomas
    • Fety R, Rolland F, Barberi-Heyob M, et al. Clinical impact of pharmacokinetically guided adaptation of 5-fluorouracil: results from a multicentre, randomized trial in patients with locally advanced head and neck carcinomas. Clin Cancer Res 1998; 4 (9): 2039-45
    • (1998) Clin Cancer Res , vol.4 , Issue.9 , pp. 2039-2045
    • Fety, R.1    Rolland, F.2    Barberi-Heyob, M.3
  • 53
    • 0031901763 scopus 로고    scopus 로고
    • Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: Results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients
    • Gamelin E, Boisdron-Celle M, Delva R, et al. Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J Clin Oncol 1998; 16 (4): 1470-8
    • (1998) J Clin Oncol , vol.16 , Issue.4 , pp. 1470-1478
    • Gamelin, E.1    Boisdron-Celle, M.2    Delva, R.3
  • 54
    • 0000020241 scopus 로고    scopus 로고
    • Multicentric randomized trial comparing in weekly treatment of advanced colorectal cancer (CRC) intensified 5-fluorouracil and folinic acid (FA) with 5-FU pharmacokinetic monitoring to a constant dose calculated with body surface area
    • Gamelin E, Jacob J, Danquechin-Dorval E, et al. Multicentric randomized trial comparing in weekly treatment of advanced colorectal cancer (CRC) intensified 5-fluorouracil and folinic acid (FA) with 5-FU pharmacokinetic monitoring to a constant dose calculated with body surface area [abstract]. Proc Am Soc Clin Oncol 1998; 17: 1039
    • (1998) Proc Am Soc Clin Oncol , vol.17 , pp. 1039
    • Gamelin, E.1    Jacob, J.2    Danquechin-Dorval, E.3
  • 55
    • 0032800786 scopus 로고    scopus 로고
    • Individual 5FU-dose adaptation schedule using bimonthly pharmacokinetically modulated LV5FU2 regimen: A feasibility study in patients with advanced colorectal cancer
    • Ychou M, Duffour J, Pinguet F, et al. Individual 5FU-dose adaptation schedule using bimonthly pharmacokinetically modulated LV5FU2 regimen: a feasibility study in patients with advanced colorectal cancer. Anticancer Res 1999; 19 (3B): 2229-36
    • (1999) Anticancer Res , vol.19 , Issue.3 B , pp. 2229-2236
    • Ychou, M.1    Duffour, J.2    Pinguet, F.3
  • 56
    • 0026633228 scopus 로고
    • Pharmacokinetically guided dosing of intravenous melphalan: A pilot study in patients with advanced ovarian adenocarcinoma
    • Ploin DY, Tranchand B, Guastalla JP, et al. Pharmacokinetically guided dosing of intravenous melphalan: a pilot study in patients with advanced ovarian adenocarcinoma. Eur J Cancer 1992; 28A (8/9): 1311-5
    • (1992) Eur J Cancer , vol.28 A , Issue.8-9 , pp. 1311-1315
    • Ploin, D.Y.1    Tranchand, B.2    Guastalla, J.P.3
  • 57
    • 0024831255 scopus 로고
    • Individualisation de posologie de methotrexate haute dose par le dosage des concentrations plasmatiques interet therapeutique dans le sarcome osteohenique
    • Delepine N, Desbois JC, Delepine G, et al. Individualisation de posologie de methotrexate haute dose par le dosage des concentrations plasmatiques interet therapeutique dans le sarcome osteohenique. Bull Cancer 1989; 76: 913-8
    • (1989) Bull Cancer , vol.76 , pp. 913-918
    • Delepine, N.1    Desbois, J.C.2    Delepine, G.3
  • 58
    • 0029009264 scopus 로고
    • Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy of osteosarcoma
    • Delepine N, Delepine G, Cornille H, et al. Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy of osteosarcoma. Anticancer Res 1995; 15 (2): 489-94
    • (1995) Anticancer Res , vol.15 , Issue.2 , pp. 489-494
    • Delepine, N.1    Delepine, G.2    Cornille, H.3
  • 59
    • 0028157622 scopus 로고
    • Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma
    • Pignon T, Lacarelle B, Duffaud F, et al. Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma. Cancer Chemother Pharmacol 1994; 33: 420-4
    • (1994) Cancer Chemother Pharmacol , vol.33 , pp. 420-424
    • Pignon, T.1    Lacarelle, B.2    Duffaud, F.3
  • 60
    • 0029125490 scopus 로고
    • Dosage adjustment of high-dose methotrexate using Bayesian estimation: A comparative study of two different concentrations at the end of 8-h infusions
    • Pignon T, Lacarelle B, Duffaud F, et al. Dosage adjustment of high-dose methotrexate using Bayesian estimation: a comparative study of two different concentrations at the end of 8-h infusions. Ther Drug Monit 1995; 17 (5): 471-8
    • (1995) Ther Drug Monit , vol.17 , Issue.5 , pp. 471-478
    • Pignon, T.1    Lacarelle, B.2    Duffaud, F.3
  • 61
    • 0033621556 scopus 로고    scopus 로고
    • Individualized methotrexate dosing in children with relapsed acute lymphoblastic leukemia
    • Wall AM, Gajjar A, Link A, et al. Individualized methotrexate dosing in children with relapsed acute lymphoblastic leukemia. Leukemia 2000; 14 (2): 221-5
    • (2000) Leukemia , vol.14 , Issue.2 , pp. 221-225
    • Wall, A.M.1    Gajjar, A.2    Link, A.3
  • 62
    • 0024365297 scopus 로고
    • Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580)
    • Conley BA, Forrest A, Egorin MJ, et al. Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580). Cancer Res 1989; 49 (12): 3436-40
    • (1989) Cancer Res , vol.49 , Issue.12 , pp. 3436-3440
    • Conley, B.A.1    Forrest, A.2    Egorin, M.J.3
  • 63
    • 0026451999 scopus 로고
    • Approaches to optimal dosing of hexamethylene bisacetamide
    • Conley BA, Egorin MJ, Sinibaldi V, et al. Approaches to optimal dosing of hexamethylene bisacetamide. Cancer Chemother Pharmacol 1992; 31 (1): 37-45
    • (1992) Cancer Chemother Pharmacol , vol.31 , Issue.1 , pp. 37-45
    • Conley, B.A.1    Egorin, M.J.2    Sinibaldi, V.3
  • 64
    • 0026695414 scopus 로고
    • Hexamethylene bisacetamide in myelodysplastic syndrome: Effect of five-day exposure to maximal therapeutic concentrations
    • Rowinsky EK, Conley BA, Jones RJ, et al. Hexamethylene bisacetamide in myelodysplastic syndrome: effect of five-day exposure to maximal therapeutic concentrations. Leukemia 1992; 6 (6): 526-34
    • (1992) Leukemia , vol.6 , Issue.6 , pp. 526-534
    • Rowinsky, E.K.1    Conley, B.A.2    Jones, R.J.3
  • 65
    • 0032999140 scopus 로고    scopus 로고
    • Phase I targeted systemic exposure study of paclitaxel in children with refractory acute leukemias
    • Woo MH, Relling MV, Sonnichsen DS, et al. Phase I targeted systemic exposure study of paclitaxel in children with refractory acute leukemias. Clin Cancer Res 1999; 5 (3): 543-9
    • (1999) Clin Cancer Res , vol.5 , Issue.3 , pp. 543-549
    • Woo, M.H.1    Relling, M.V.2    Sonnichsen, D.S.3
  • 66
    • 0027132214 scopus 로고
    • Suramin: Development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer
    • Jodrell DI, Reyno LM, Sridhara R, et al. Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer. J Clin Oncol 1994; 12 (1): 166-75
    • (1994) J Clin Oncol , vol.12 , Issue.1 , pp. 166-175
    • Jodrell, D.I.1    Reyno, L.M.2    Sridhara, R.3
  • 67
    • 0028241397 scopus 로고
    • Adaptive control with feedback of suramin using intermittent infusions
    • Figg WD, Stevens JA, Cooper MR. Adaptive control with feedback of suramin using intermittent infusions. J Clin Oncol 1994; 12 (7): 1523-4
    • (1994) J Clin Oncol , vol.12 , Issue.7 , pp. 1523-1524
    • Figg, W.D.1    Stevens, J.A.2    Cooper, M.R.3
  • 68
    • 0029983725 scopus 로고    scopus 로고
    • Suramin in hormone-refractory metastatic prostate cancer: A drug with limited efficacy
    • Rosen PJ, Mendoza EF, Landaw EM, et al. Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy. J Clin Oncol 1996; 14 (5): 1626-36
    • (1996) J Clin Oncol , vol.14 , Issue.5 , pp. 1626-1636
    • Rosen, P.J.1    Mendoza, E.F.2    Landaw, E.M.3
  • 69
    • 0027477057 scopus 로고
    • Escalating teniposide systemic exposure to increase dose intensity for pediatric patients
    • Rodman JH, Furman WL, Sunderland M, et al. Escalating teniposide systemic exposure to increase dose intensity for pediatric patients. J Clin Oncol 1993; 11 (2): 287-93
    • (1993) J Clin Oncol , vol.11 , Issue.2 , pp. 287-293
    • Rodman, J.H.1    Furman, W.L.2    Sunderland, M.3
  • 70
    • 0029991006 scopus 로고    scopus 로고
    • Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia
    • Furman WL, Baker SD, Pratt CB, et al. Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia. J Clin Oncol 1996; 14 (5): 1504-11
    • (1996) J Clin Oncol , vol.14 , Issue.5 , pp. 1504-1511
    • Furman, W.L.1    Baker, S.D.2    Pratt, C.B.3
  • 71
    • 0036187723 scopus 로고    scopus 로고
    • Individual adaptive dosing of topotecan in ovarian cancer
    • Montazeri A, Culine S, Laguerre B, et al. Individual adaptive dosing of topotecan in ovarian cancer. Clin Cancer Res 2002; 8 (2): 394-9
    • (2002) Clin Cancer Res , vol.8 , Issue.2 , pp. 394-399
    • Montazeri, A.1    Culine, S.2    Laguerre, B.3
  • 72
    • 0025279445 scopus 로고
    • Pharmacokinetics of continuous infusion of methotrexate and teniposide in pediatric cancer patients
    • Rodman JH, Sunderland M, Kavanagh RL, et al. Pharmacokinetics of continuous infusion of methotrexate and teniposide in pediatric cancer patients. Cancer Res 1990; 50 (14): 4267-71
    • (1990) Cancer Res , vol.50 , Issue.14 , pp. 4267-4271
    • Rodman, J.H.1    Sunderland, M.2    Kavanagh, R.L.3
  • 73
    • 0025856668 scopus 로고
    • Individualized dosages of chemotherapy as a strategy to improve response for acute lymphocytic leukemia
    • Evans WE, Rodman J, Relling MV, et al. Individualized dosages of chemotherapy as a strategy to improve response for acute lymphocytic leukemia. Semin Hematol 1991; 28 (3) Suppl. 4: 15-21
    • (1991) Semin Hematol , vol.28 , Issue.3 SUPPL. 4 , pp. 15-21
    • Evans, W.E.1    Rodman, J.2    Relling, M.V.3
  • 74
    • 0032545976 scopus 로고    scopus 로고
    • Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia
    • Evans WE, Relling MV, Rodman JH, et al. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 1998; 338 (8); 499-505
    • (1998) N Engl J Med , vol.338 , Issue.8 , pp. 499-505
    • Evans, W.E.1    Relling, M.V.2    Rodman, J.H.3
  • 75
    • 0025043402 scopus 로고
    • Rationales for a pharmacologically optimized treatment of acute nonlymphocytic leukemia with cytosine arabinoside
    • Heinemann V, Jehn U. Rationales for a pharmacologically optimized treatment of acute nonlymphocytic leukemia with cytosine arabinoside. Leukemia 1990; 4(11): 790-6
    • (1990) Leukemia , vol.4 , Issue.11 , pp. 790-796
    • Heinemann, V.1    Jehn, U.2
  • 76
    • 0030038773 scopus 로고    scopus 로고
    • Relationship between the exposure to cisplatin, DNA-adduct formation in leukocytes and tumor response in patients with solid tumors
    • Schellens JHM, Ma J, Planting AS, et al. Relationship between the exposure to cisplatin, DNA-adduct formation in leukocytes and tumor response in patients with solid tumors. Br J Cancer 1996; 73 (12): 1569-75
    • (1996) Br J Cancer , vol.73 , Issue.12 , pp. 1569-1575
    • Schellens, J.H.M.1    Ma, J.2    Planting, A.S.3
  • 77
    • 0031940674 scopus 로고    scopus 로고
    • A general model for time-dissociated pharmacokinetic-pharmacodynamic relationships exemplified by paclitaxel myelosuppression
    • Karlsson MO, Molnar V, Bergh J, et al. A general model for time-dissociated pharmacokinetic-pharmacodynamic relationships exemplified by paclitaxel myelosuppression. Clin Pharmacol Ther 1998; 63 (1): 11-25
    • (1998) Clin Pharmacol Ther , vol.63 , Issue.1 , pp. 11-25
    • Karlsson, M.O.1    Molnar, V.2    Bergh, J.3
  • 78
    • 13344269002 scopus 로고    scopus 로고
    • Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU
    • Gamelin EC, Danquechin-Dorval EM, Dumesnil YF, et al. Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer 1996; 77 (3): 441-51
    • (1996) Cancer , vol.77 , Issue.3 , pp. 441-451
    • Gamelin, E.C.1    Danquechin-Dorval, E.M.2    Dumesnil, Y.F.3
  • 79
    • 0024266208 scopus 로고
    • More is better
    • Hryniuk WM. More is better. J Clin Oncol 1988; 6 (9): 1365-7
    • (1988) J Clin Oncol , vol.6 , Issue.9 , pp. 1365-1367
    • Hryniuk, W.M.1
  • 80
    • 0023101182 scopus 로고
    • A phase I and pharmacokinetic study of hexamethylene bisacetamide (HMBA, NSC95580) administered as a five day continuous infusion
    • Egorin MJ, Sigman LM, Van Echo DA, et al. A phase I and pharmacokinetic study of hexamethylene bisacetamide (HMBA, NSC95580) administered as a five day continuous infusion. Cancer Res 1987; 47 (2): 617-23
    • (1987) Cancer Res , vol.47 , Issue.2 , pp. 617-623
    • Egorin, M.J.1    Sigman, L.M.2    Van Echo, D.A.3
  • 81
    • 0345263738 scopus 로고    scopus 로고
    • Target dose adjustment of busulphan using pharmacokinetic parameters in pediatric patients undergoing bone marrow transplantation for malignancy or inborn errors
    • Bolinger AM, Zangwill AB, Slattery JT, et al. Target dose adjustment of busulphan using pharmacokinetic parameters in pediatric patients undergoing bone marrow transplantation for malignancy or inborn errors [abstract]. Blood 1997; 90: 374a
    • (1997) Blood , vol.90
    • Bolinger, A.M.1    Zangwill, A.B.2    Slattery, J.T.3
  • 82
    • 0034699950 scopus 로고    scopus 로고
    • Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: A randomized trial
    • Bergh J, Wiklund T, Erikstein B, et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomized trial. Lancet 2000; 356: 1284-391
    • (2000) Lancet , vol.356 , pp. 1284-1391
    • Bergh, J.1    Wiklund, T.2    Erikstein, B.3
  • 83
    • 0032774739 scopus 로고    scopus 로고
    • Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF
    • Poikonen P, Saarto T, Lundin J, et al. Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer 1999; 80 (11): 1763-6
    • (1999) Br J Cancer , vol.80 , Issue.11 , pp. 1763-1766
    • Poikonen, P.1    Saarto, T.2    Lundin, J.3
  • 84
    • 0024345093 scopus 로고
    • Pharmacokinetics of busulphan: Correlations with veno-occlusive disease in patients undergoing bone marrow transplantation
    • Grochow LB, Jones RJ, Brundrett RB, et al. Pharmacokinetics of busulphan: correlations with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989; 25 (1): 55-61
    • (1989) Cancer Chemother Pharmacol , vol.25 , Issue.1 , pp. 55-61
    • Grochow, L.B.1    Jones, R.J.2    Brundrett, R.B.3
  • 85
    • 0023303814 scopus 로고
    • Reappraisal of some dosage adjustment guidelines
    • Sulkes A, Collins JM. Reappraisal of some dosage adjustment guidelines. Cancer Treat Rep 1987; 71 (3): 229-33
    • (1987) Cancer Treat Rep , vol.71 , Issue.3 , pp. 229-233
    • Sulkes, A.1    Collins, J.M.2
  • 87
    • 0027443965 scopus 로고
    • Individualizing drug dosage regimens: Roles of population pharmacokinetic and dynamic models, Bayesian fitting and adaptive control
    • Jelliffe RW, Schumitzky A, Van Guilder M, et al. Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting and adaptive control. Ther Drug Monit 1993; 15 (5): 380-93
    • (1993) Ther Drug Monit , vol.15 , Issue.5 , pp. 380-393
    • Jelliffe, R.W.1    Schumitzky, A.2    Van Guilder, M.3
  • 88
    • 0022353917 scopus 로고
    • Feedback control methods for drug dosage optimisation: Concepts, classification and clinical application
    • Vozeh S, Steimer JL. Feedback control methods for drug dosage optimisation: concepts, classification and clinical application. Clin Pharmacokinet 1985; 10 (6): 457-76
    • (1985) Clin Pharmacokinet , vol.10 , Issue.6 , pp. 457-476
    • Vozeh, S.1    Steimer, J.L.2
  • 89
    • 0031691162 scopus 로고    scopus 로고
    • Expanding clinical applications of population pharmacokinetic modelling
    • Minto C, Schnider T. Expanding clinical applications of population pharmacokinetic modelling. Br J Clin Pharmacol 1998; 46 (4): 321-33
    • (1998) Br J Clin Pharmacol , vol.46 , Issue.4 , pp. 321-333
    • Minto, C.1    Schnider, T.2
  • 90
    • 0031824697 scopus 로고    scopus 로고
    • Methodological issues in pharmacokinetic-pharmacodynamic modelling
    • Bellissant E, Sebille V, Paintaud G. Methodological issues in pharmacokinetic-pharmacodynamic modelling. Clin Pharmacokinet 1998; 35 (2): 151-66
    • (1998) Clin Pharmacokinet , vol.35 , Issue.2 , pp. 151-166
    • Bellissant, E.1    Sebille, V.2    Paintaud, G.3
  • 92
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors
    • Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-16
    • (2000) J Natl Cancer Inst , vol.92 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhauer, E.A.3
  • 93
    • 0003506753 scopus 로고
    • Bethesda (MD): National Cancer Institute, Division of Cancer Treatment
    • Guidelines for reporting of adverse drug reactions. Bethesda (MD): National Cancer Institute, Division of Cancer Treatment, 1988
    • (1988) Guidelines for Reporting of Adverse Drug Reactions
  • 94
    • 0026580927 scopus 로고
    • Mw/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring
    • Proost JH, Meijer DKF. Mw/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med 1992; 22 (3): 155-63
    • (1992) Comput Biol Med , vol.22 , Issue.3 , pp. 155-163
    • Proost, J.H.1    Meijer, D.K.F.2
  • 95
    • 0033823462 scopus 로고    scopus 로고
    • Plasma concentration monitoring of busulphan: Does it improve clinical outcome?
    • McCune JS, Gibbs JP, Slattery JT. Plasma concentration monitoring of busulphan: does it improve clinical outcome? Clin Pharmacokinet 2000; 39 (2): 155-65
    • (2000) Clin Pharmacokinet , vol.39 , Issue.2 , pp. 155-165
    • McCune, J.S.1    Gibbs, J.P.2    Slattery, J.T.3
  • 96
    • 0031711811 scopus 로고    scopus 로고
    • Therapeutic monitoring of busulphan in hematopoietic stem cell transplantation
    • Slattery JT, Risler LJ. Therapeutic monitoring of busulphan in hematopoietic stem cell transplantation. Ther Drug Monit 1998; 20 (5): 543-9
    • (1998) Ther Drug Monit , vol.20 , Issue.5 , pp. 543-549
    • Slattery, J.T.1    Risler, L.J.2
  • 97
    • 0024440650 scopus 로고
    • Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
    • Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7 (11): 1748-56
    • (1989) J Clin Oncol , vol.7 , Issue.11 , pp. 1748-1756
    • Calvert, A.H.1    Newell, D.R.2    Gumbrell, L.A.3
  • 98
    • 0022379952 scopus 로고
    • Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedi- carboxylatoplatinum
    • Egorin MJ, Van Echo DA, Olman EA, et al. Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedi-carboxylatoplatinum. Cancer Res 1985; 45: 6502-6
    • (1985) Cancer Res , vol.45 , pp. 6502-6506
    • Egorin, M.J.1    Van Echo, D.A.2    Olman, E.A.3
  • 99
    • 0028936713 scopus 로고
    • Prediction of carboplatin clearance from standard morphological and biological patient characteristics
    • Chatelut E, Canal P, Brunner V, et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 1995; 87 (8): 573-80
    • (1995) J Natl Cancer Inst , vol.87 , Issue.8 , pp. 573-580
    • Chatelut, E.1    Canal, P.2    Brunner, V.3
  • 100
    • 0027488001 scopus 로고
    • Carboplatin pharmacokinetics in children: The development of a pediatric dosing formula
    • Newell DR, Pearson AD, Balmanno K, et al. Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. J Clin Oncol 1993; 11 (12): 2314-23
    • (1993) J Clin Oncol , vol.11 , Issue.12 , pp. 2314-2323
    • Newell, D.R.1    Pearson, A.D.2    Balmanno, K.3
  • 101
    • 0033015578 scopus 로고    scopus 로고
    • Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer: Status of the art
    • Gamelin E, Boisdron-Celle M. Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer: status of the art. Clin Rev Oncol Hematol 1999; 30 (1): 71-9
    • (1999) Clin Rev Oncol Hematol , vol.30 , Issue.1 , pp. 71-79
    • Gamelin, E.1    Boisdron-Celle, M.2
  • 102
    • 0027980646 scopus 로고
    • Patient characteristics associated with high-risk methotrexate concentrations and toxicity
    • Relling MV, Fairclough D, Ayers D, et al. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol 1994; 12 (8): 1667-72
    • (1994) J Clin Oncol , vol.12 , Issue.8 , pp. 1667-1672
    • Relling, M.V.1    Fairclough, D.2    Ayers, D.3
  • 103
    • 17644399981 scopus 로고    scopus 로고
    • Pharmacokinetically guided dosing of cyclophosphamide, thiotepa and carboplatin in high dose chemotherapy
    • De Jonge ME, Huitema ADR, Van Dam SM, et al. Pharmacokinetically guided dosing of cyclophosphamide, thiotepa and carboplatin in high dose chemotherapy. Proc Am Soc Clin Oncol 2003; 22: 562
    • (2003) Proc Am Soc Clin Oncol , vol.22 , pp. 562
    • De Jonge, M.E.1    Huitema, A.D.R.2    Van Dam, S.M.3
  • 104
    • 0036230253 scopus 로고    scopus 로고
    • Cancer genetics and their application to individualized medicine
    • Liefers GJ, Tollenaar RAEM. Cancer genetics and their application to individualized medicine. Eur J Cancer 2002; 38 (7): 872-9
    • (2002) Eur J Cancer , vol.38 , Issue.7 , pp. 872-879
    • Liefers, G.J.1    Tollenaar, R.A.E.M.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.